150 related articles for article (PubMed ID: 34671649)
1. Sex Differences in Platelet Reactivity in Patients With ST-Elevation Myocardial Infarction: A Sub-Analysis of the ON-TIME 3 Trial.
Tavenier AH; Hermanides RS; Ottervanger JP; Belitser SV; Klungel OH; Appelman Y; van Leeuwen MAH; van 't Hof AWJ
Front Cardiovasc Med; 2021; 8():707814. PubMed ID: 34671649
[No Abstract] [Full Text] [Related]
2. Impact of opioids on P2Y12 receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: Opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial.
Tavenier AH; Hermanides RS; Ottervanger JP; Tolsma R; van Beurden A; Slingerland RJ; Ter Horst PGJ; Gosselink ATM; Dambrink JE; van Leeuwen MAH; Roolvink V; Kedhi E; Klungel OH; Belitser SV; Angiolillo DJ; Pustjens T; Rasoul S; Gho B; Stein M; Ruiters L; van 't Hof AWJ
Eur Heart J Cardiovasc Pharmacother; 2022 Jan; 8(1):4-12. PubMed ID: 32730628
[TBL] [Abstract][Full Text] [Related]
3. A randomised, investigator-initiated, clinical trial of the effects of fentanyl on P2Y12-receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: rationale and design of the Opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial.
Tavenier AH; Hermanides RS; Ottervanger JP; Rasoul S; Slingerland RJ; Tolsma R; van Workum S; Kedhi E; van 't Hof AWJ
Neth Heart J; 2019 Apr; 27(4):185-190. PubMed ID: 30767166
[TBL] [Abstract][Full Text] [Related]
4. Differential impact of fentanyl and morphine doses on ticagrelor-induced platelet inhibition in ST-segment elevation myocardial infarction: a subgroup analysis from the PERSEUS randomized trial.
Garin D; Degrauwe S; Carbone F; Musayeb Y; Lauriers N; Valgimigli M; Iglesias JF
Front Cardiovasc Med; 2024; 11():1324641. PubMed ID: 38628315
[TBL] [Abstract][Full Text] [Related]
5. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
Kunadian V; James SK; Wojdyla DM; Zorkun C; Wu J; Storey RF; Steg PG; Katus H; Emanuelsson H; Horrow J; Maya J; Wallentin L; Harrington RA; Gibson CM
JACC Cardiovasc Interv; 2013 Jul; 6(7):671-83. PubMed ID: 23866179
[TBL] [Abstract][Full Text] [Related]
6. Long-term pharmacodynamic effects of Ticagrelor versus Clopidogrel in fibrinolytic-treated STEMI patients undergoing early PCI.
Yang A; Pon Q; Lavoie A; Crawford JJ; Harenberg S; Zimmermann RH; Booker J; Kelly S; Lavi S; Cantor WJ; Mehta SR; Bagai A; Goodman SG; Cheema AN; Dehghani P
J Thromb Thrombolysis; 2018 Feb; 45(2):225-233. PubMed ID: 29170875
[TBL] [Abstract][Full Text] [Related]
7. Comparative effects of fentanyl versus morphine on platelet inhibition induced by ticagrelor in patients with ST-segment elevation myocardial infarction: Full results of the PERSEUS randomized trial.
Iglesias JF; Valgimigli M; Carbone F; Lauriers N; Masci PG; Degrauwe S
Cardiol J; 2022; 29(4):591-600. PubMed ID: 35762079
[TBL] [Abstract][Full Text] [Related]
8. Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patients undergoing early PCI.
Dehghani P; Lavoie A; Lavi S; Crawford JJ; Harenberg S; Zimmermann RH; Booker J; Kelly S; Cantor WJ; Mehta SR; Bagai A; Goodman SG; Cheema AN
Am Heart J; 2017 Oct; 192():105-112. PubMed ID: 28938956
[TBL] [Abstract][Full Text] [Related]
9. P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. The PRIVATE-ATLANTIC study.
Silvain J; Storey RF; Cayla G; Esteve JB; Dillinger JG; Rousseau H; Tsatsaris A; Baradat C; Salhi N; Hamm CW; Lapostolle F; Lassen JF; Collet JP; Ten Berg JM; Van't Hof AW; Montalescot G
Thromb Haemost; 2016 Aug; 116(2):369-78. PubMed ID: 27196998
[TBL] [Abstract][Full Text] [Related]
10. Effect of Pre-Hospital Ticagrelor During the First 24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction: The ATLANTIC-H²⁴ Analysis.
Montalescot G; van 't Hof AW; Bolognese L; Cantor WJ; Cequier A; Chettibi M; Collet JP; Goodman SG; Hammett CJ; Huber K; Janzon M; Lapostolle F; Lassen JF; Licour M; Merkely B; Salhi N; Silvain J; Storey RF; Ten Berg JM; Tsatsaris A; Zeymer U; Vicaut E; Hamm CW;
JACC Cardiovasc Interv; 2016 Apr; 9(7):646-56. PubMed ID: 26952907
[TBL] [Abstract][Full Text] [Related]
11. Residual platelet reactivity after pre-treatment with ticagrelor prior to primary percutaneous coronary intervention is associated with suboptimal myocardial reperfusion.
Roule V; Heudel T; Lemaitre A; Bignon M; Ardouin P; Sabatier R; Blanchart K; Beygui F
Eur Heart J Acute Cardiovasc Care; 2019 Aug; ():. PubMed ID: 31402681
[TBL] [Abstract][Full Text] [Related]
12. Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic Investigation.
Franchi F; Rollini F; Cho JR; Bhatti M; DeGroat C; Ferrante E; Dunn EC; Nanavati A; Carraway E; Suryadevara S; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2015 Sep; 8(11):1457-1467. PubMed ID: 26404199
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-Segment Elevation Myocardial Infarction.
Lee YS; Jin CD; Kim MH; Guo LZ; Cho YR; Park K; Park JS; Park TH; Kim YD
Circ J; 2015; 79(6):1248-54. PubMed ID: 25959558
[TBL] [Abstract][Full Text] [Related]
14. Association between gender and short-term outcome in patients with ST elevation myocardial infraction participating in the international, prospective, randomised Administration of Ticagrelor in the catheterisation Laboratory or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) trial: a prespecified analysis.
Venetsanos D; Sederholm Lawesson S; Alfredsson J; Janzon M; Cequier A; Chettibi M; Goodman SG; Van't Hof AW; Montalescot G; Swahn E
BMJ Open; 2017 Sep; 7(9):e015241. PubMed ID: 28939567
[TBL] [Abstract][Full Text] [Related]
15. Cangrelor in combination with ticagrelor provides consistent and potent P2Y12-inhibition during and after primary percutaneous coronary intervention in real-world patients with ST-segment-elevation myocardial infarction.
Mohammad MA; Andell P; Koul S; James S; Scherstén F; Götberg M; Erlinge D
Platelets; 2017 Jun; 28(4):414-416. PubMed ID: 27885888
[TBL] [Abstract][Full Text] [Related]
16. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study.
Parodi G; Valenti R; Bellandi B; Migliorini A; Marcucci R; Comito V; Carrabba N; Santini A; Gensini GF; Abbate R; Antoniucci D
J Am Coll Cardiol; 2013 Apr; 61(15):1601-6. PubMed ID: 23500251
[TBL] [Abstract][Full Text] [Related]
17. Influence of intravenous fentanyl compared with morphine on ticagrelor absorption and platelet inhibition in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the PERSEUS randomized trial.
Degrauwe S; Roffi M; Lauriers N; Muller O; Masci PG; Valgimigli M; Iglesias JF
Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):158-163. PubMed ID: 30101278
[TBL] [Abstract][Full Text] [Related]
18. [The variation of serum uric acid levels among patients with myocardial infarction treated with ticagrelor and the association between serum uric acid and platelet reactivity].
Song L; Xu DY; Zhou P; Liu C; Sheng ZX; Li JN; Zhou JY; Chen RZ; Chen Y; Zhao HJ; Yan HB
Zhonghua Xin Xue Guan Bing Za Zhi; 2021 Feb; 49(2):170-175. PubMed ID: 33611904
[No Abstract] [Full Text] [Related]
19. Platelet effect of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction.
Kerneis M; Silvain J; Abtan J; Hauguel M; Barthélémy O; Payot L; Brugier D; Galier S; Collet JP; Montalescot G
Arch Cardiovasc Dis; 2015 Oct; 108(10):502-10. PubMed ID: 26113480
[TBL] [Abstract][Full Text] [Related]
20. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Franchi F; Rollini F; Rivas A; Wali M; Briceno M; Agarwal M; Shaikh Z; Nawaz A; Silva G; Been L; Smairat R; Kaufman M; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ
Circulation; 2019 Apr; 139(14):1661-1670. PubMed ID: 30630341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
